Loading...
Several large epidemiologic studies have raised concern that drospirenone-containing oral contraceptives (OCs) are more likely than levonorgestrel-containing OCs to be associated with thromboembolic events, although the industry-funded European Active Surveillance Study did not find this to be the case. Now, investigators for the industry-funded International Active Surveillance Study of Women Taking Oral Contraceptives have reported outcomes in >85,000 participants (22% of whom were new users of combined hormonal contraception) who were prospectively followed for 2 to 6 years with only 3.3% lost to follow-up.
Whether women used 21- or 24-day regimens of drospirenone-containing combined OCs, rates of thromboembolism were less than 1 per 1000…